https://www.selleckchem.com/pr....oducts/gsk2141795.ht
Antibody-drug conjugates (ADCs) are a class of biopharmaceuticals in which cytotoxic agents are conjugated to monoclonal antibodies (mAbs), allowing targeted drug delivery. Present heterogeneous ADCs (conjugated in random variable positions) suffered from issues of stability, reproducibility, efficacy, etc. Recent advances have led to the development of homogeneous ADC preparations by site-specific conjugation, allowing the control of the drug-to-antibody ratio. These approaches have increased the therapeutic window, efficacy, and ba
Beğen
Yorum Yap
Paylaş
